By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: RSNA 2013: Advancing Towards an HIV Cure?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Radiology > RSNA 2013: Advancing Towards an HIV Cure?
Radiology

RSNA 2013: Advancing Towards an HIV Cure?

Steve Goldstein
Steve Goldstein
Share
4 Min Read
RSNA 2013 HIV research
SHARE

Can radioimmunotherapy (RIT) be effective in helping to find a cure for the human immunodeficiency virus (HIV)? Researchers have used RIT to destroy remaining HIV-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the research were presented Tuesday at the annual meeting of the Radiological Society of North America in Chicago.

Can radioimmunotherapy (RIT) be effective in helping to find a cure for the human immunodeficiency virus (HIV)? Researchers have used RIT to destroy remaining HIV-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the research were presented Tuesday at the annual meeting of the Radiological Society of North America in Chicago.

What is known as highly active retroviral therapy (HAART) has brightened the outlook for patients infected with HIV by suppressing the replication of the virus in the body. Despite the success of HAART in effectively reducing the burden of HIV, however, scientists believe reservoirs of latently infected cells persist in the body, stalling the possibility of a permanent cure.

RSNA 2013 HIV research“In an HIV patient on HAART, drugs suppress viral replication, which means they keep the number of viral particles in a patient’s bloodstream very low. However, HAART cannot kill the HIV-infected cells,” said the study’s lead author, Ekaterina Dadachova, Ph.D., professor of radiology, microbiology and immunology at Albert Einstein College of Medicine in the Bronx, N.Y. “Any strategy for curing HIV infection must include a method to eliminate viral-infected cells.”

More Read

Image
Possible Decline in Pediatric CT Use
Imaging Portals Drive Patient Engagement and Satisfaction
Mammography Scheduling Portal Helps Improve Screening Attendance in Denmark
Mobile Health Around the Globe: Russia Uses mHealth to Help High Risk Patients
The Essential Cheat Sheet on Radiology Billing

Is RIT the right method? In her study, Dr. Dadachova and a team of researchers administered RIT to blood samples from HIV patients treated with HAART. RIT, traditionally used in cancer treatment, uses monoclonal antibodies — cloned cells that are recruited by the immune system to identify and neutralize antigens. Antigens are foreign objects like bacteria and viruses that stimulate an immune response in the body. The antibody, designed to recognize and bind to a specific cell antigen, is paired with a radioactive isotope. When injected into a patient’s bloodstream, the lab-developed antibody travels to the target cell where the radiation is then delivered.

“In RIT, the antibodies bind to the infected cells and kill them by radiation,” Dr Dadachova said. “When HAART and RIT are used together, they kill the virus and infected cells, respectively.”

The researchers found that RIT was able to kill HIV-infected lymphocytes previously treated with HAART, reducing the HIV infection in blood samples to undetectable levels. “The elimination of HIV infected cells with RIT was profound and specific,” said Dr. Dadachova. “The radionuclide we used delivered radiation only to HIV-infected cells without damaging nearby cells.”

Clinical trials in HIV patients are the next step for the RIT treatment, said Dr. Dadachova.

 

Click here for more information about Siemens at RSNA:

http://sie.ag/1dRNAEf

TAGGED:Ekaterina DadachovaHIVradioimmunologyRSNA 2013
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

Using Teleradiology to Become Independent from RIS [VIDEO]

August 7, 2014

Patient Care Over There: A Talk About Global Radiology Practices

August 10, 2014

Fast-Forward Scanning

August 11, 2014

5 Tips for Preventing Reimbursement Loss in Radiology Billing

August 2, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?